Kiora Begin Period Cash Flow vs Stock Based Compensation Analysis

KPRX Stock

USD 3.32 0.19 5.41%

Kiora Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiora Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiora Pharmaceuticals is a good investment. Please check the relationship between Kiora Pharmaceuticals Begin Period Cash Flow and its Stock Based Compensation accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.

Begin Period Cash Flow vs Stock Based Compensation

Begin Period Cash Flow vs Stock Based Compensation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiora Pharmaceuticals Begin Period Cash Flow account and Stock Based Compensation. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Kiora Pharmaceuticals' Begin Period Cash Flow and Stock Based Compensation is -0.08. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Stock Based Compensation in the same time period over historical financial statements of Kiora Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiora Pharmaceuticals' Begin Period Cash Flow and Stock Based Compensation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Kiora Pharmaceuticals are associated (or correlated) with its Stock Based Compensation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Stock Based Compensation has no effect on the direction of Begin Period Cash Flow i.e., Kiora Pharmaceuticals' Begin Period Cash Flow and Stock Based Compensation go up and down completely randomly.

Correlation Coefficient

-0.08

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Most indicators from Kiora Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiora Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiora Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Kiora Stock please use our How to Invest in Kiora Pharmaceuticals guide.At this time, Kiora Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 94.8 K in 2024, whereas Enterprise Value Over EBITDA is likely to drop (0.02) in 2024.

Kiora Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Current Deferred Revenue	Good Will	Intangible Assets	Other Liab
Total Assets		-0.49	0.85	0.23	0.93	0.73	-0.68	-0.82	0.31	0.67	0.88	-0.5	0.67	0.43	0.59	-0.88	0.76	0.95	-0.87	0.76	-0.48	0.49	0.47	-0.73	0.61	0.65
Short Long Term Debt Total	-0.49		-0.54	0.04	-0.55	-0.26	0.69	0.33	-0.03	-0.52	-0.3	0.76	-0.52	-0.23	-0.22	0.51	-0.34	-0.44	0.55	-0.54	1.0	-0.3	-0.29	0.3	-0.13	-0.21
Other Current Liab	0.85	-0.54		0.48	0.82	0.52	-0.62	-0.68	0.63	0.59	0.73	-0.51	0.59	0.4	0.56	-0.84	0.56	0.8	-0.77	0.67	-0.53	0.31	0.65	-0.48	0.5	0.47
Total Current Liabilities	0.23	0.04	0.48		0.18	-0.04	-0.32	-0.01	0.56	0.39	0.08	0.22	0.39	-0.15	-0.15	-0.36	0.25	0.1	-0.14	0.35	0.04	0.34	0.88	0.26	-0.18	-0.24
Total Stockholder Equity	0.93	-0.55	0.82	0.18		0.56	-0.69	-0.79	0.3	0.69	0.77	-0.6	0.69	0.47	0.51	-0.97	0.68	0.92	-0.99	0.76	-0.55	0.51	0.42	-0.69	0.43	0.56
Property Plant And Equipment Net	0.73	-0.26	0.52	-0.04	0.56		-0.5	-0.67	0.11	0.53	0.6	-0.33	0.53	0.46	0.62	-0.45	0.74	0.7	-0.48	0.61	-0.24	0.17	0.15	-0.71	0.66	0.7
Net Debt	-0.68	0.69	-0.62	-0.32	-0.69	-0.5		0.31	-0.15	-0.96	-0.27	0.52	-0.96	-0.14	-0.13	0.71	-0.58	-0.53	0.69	-0.95	0.67	-0.61	-0.45	0.31	-0.03	-0.08
Retained Earnings	-0.82	0.33	-0.68	-0.01	-0.79	-0.67	0.31		-0.11	-0.35	-0.82	0.45	-0.35	-0.77	-0.86	0.68	-0.57	-0.89	0.7	-0.48	0.32	-0.26	-0.34	0.91	-0.7	-0.91
Accounts Payable	0.31	-0.03	0.63	0.56	0.3	0.11	-0.15	-0.11		0.15	0.31	0.09	0.15	0.01	0.14	-0.41	0.15	0.25	-0.29	0.18	-0.02	-0.05	0.37	0.11	0.21	-0.01
Cash	0.67	-0.52	0.59	0.39	0.69	0.53	-0.96	-0.35	0.15		0.24	-0.41	1.0	0.21	0.18	-0.71	0.6	0.51	-0.67	0.98	-0.51	0.65	0.49	-0.35	0.03	0.12
Non Current Assets Total	0.88	-0.3	0.73	0.08	0.77	0.6	-0.27	-0.82	0.31	0.24		-0.38	0.24	0.36	0.61	-0.7	0.64	0.9	-0.7	0.35	-0.3	0.26	0.32	-0.7	0.75	0.74
Non Currrent Assets Other	-0.5	0.76	-0.51	0.22	-0.6	-0.33	0.52	0.45	0.09	-0.41	-0.38		-0.41	-0.36	-0.34	0.53	-0.33	-0.52	0.62	-0.46	0.76	-0.26	-0.09	0.44	-0.27	-0.38
Cash And Short Term Investments	0.67	-0.52	0.59	0.39	0.69	0.53	-0.96	-0.35	0.15	1.0	0.24	-0.41		0.21	0.18	-0.71	0.6	0.51	-0.67	0.98	-0.51	0.65	0.49	-0.35	0.03	0.12
Net Receivables	0.43	-0.23	0.4	-0.15	0.47	0.46	-0.14	-0.77	0.01	0.21	0.36	-0.36	0.21		0.87	-0.34	0.06	0.53	-0.41	0.35	-0.22	-0.03	0.09	-0.67	0.61	0.8
Common Stock Shares Outstanding	0.59	-0.22	0.56	-0.15	0.51	0.62	-0.13	-0.86	0.14	0.18	0.61	-0.34	0.18	0.87		-0.37	0.21	0.68	-0.43	0.32	-0.2	-0.03	0.09	-0.82	0.78	0.88
Non Current Liabilities Total	-0.88	0.51	-0.84	-0.36	-0.97	-0.45	0.71	0.68	-0.41	-0.71	-0.7	0.53	-0.71	-0.34	-0.37		-0.66	-0.86	0.97	-0.77	0.51	-0.55	-0.54	0.55	-0.28	-0.39
Other Current Assets	0.76	-0.34	0.56	0.25	0.68	0.74	-0.58	-0.57	0.15	0.6	0.64	-0.33	0.6	0.06	0.21	-0.66		0.69	-0.62	0.61	-0.34	0.44	0.46	-0.55	0.3	0.42
Other Stockholder Equity	0.95	-0.44	0.8	0.1	0.92	0.7	-0.53	-0.89	0.25	0.51	0.9	-0.52	0.51	0.53	0.68	-0.86	0.69		-0.88	0.63	-0.43	0.39	0.37	-0.82	0.63	0.73
Total Liab	-0.87	0.55	-0.77	-0.14	-0.99	-0.48	0.69	0.7	-0.29	-0.67	-0.7	0.62	-0.67	-0.41	-0.43	0.97	-0.62	-0.88		-0.74	0.55	-0.5	-0.35	0.63	-0.34	-0.47
Total Current Assets	0.76	-0.54	0.67	0.35	0.76	0.61	-0.95	-0.48	0.18	0.98	0.35	-0.46	0.98	0.35	0.32	-0.77	0.61	0.63	-0.74		-0.53	0.61	0.48	-0.46	0.16	0.26
Short Term Debt	-0.48	1.0	-0.53	0.04	-0.55	-0.24	0.67	0.32	-0.02	-0.51	-0.3	0.76	-0.51	-0.22	-0.2	0.51	-0.34	-0.43	0.55	-0.53		-0.3	-0.29	0.28	-0.13	-0.21
Common Stock	0.49	-0.3	0.31	0.34	0.51	0.17	-0.61	-0.26	-0.05	0.65	0.26	-0.26	0.65	-0.03	-0.03	-0.55	0.44	0.39	-0.5	0.61	-0.3		0.37	-0.3	-0.2	-0.02
Current Deferred Revenue	0.47	-0.29	0.65	0.88	0.42	0.15	-0.45	-0.34	0.37	0.49	0.32	-0.09	0.49	0.09	0.09	-0.54	0.46	0.37	-0.35	0.48	-0.29	0.37		-0.05	0.02	0.08
Good Will	-0.73	0.3	-0.48	0.26	-0.69	-0.71	0.31	0.91	0.11	-0.35	-0.7	0.44	-0.35	-0.67	-0.82	0.55	-0.55	-0.82	0.63	-0.46	0.28	-0.3	-0.05		-0.59	-0.83
Intangible Assets	0.61	-0.13	0.5	-0.18	0.43	0.66	-0.03	-0.7	0.21	0.03	0.75	-0.27	0.03	0.61	0.78	-0.28	0.3	0.63	-0.34	0.16	-0.13	-0.2	0.02	-0.59		0.88
Other Liab	0.65	-0.21	0.47	-0.24	0.56	0.7	-0.08	-0.91	-0.01	0.12	0.74	-0.38	0.12	0.8	0.88	-0.39	0.42	0.73	-0.47	0.26	-0.21	-0.02	0.08	-0.83	0.88

Click cells to compare fundamentals

Kiora Pharmaceuticals Account Relationship Matchups

Kiora Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	10.1M	15.2M	18.1M	18.7M	13.7M	11.7M
Short Long Term Debt Total	83.9K	362.1K	209.4K	105.8K	106.9K	101.5K
Other Current Liab	1.1M	1.3M	1.2M	2.1M	1.3M	1.3M
Total Current Liabilities	1.4M	1.8M	1.6M	3.3M	1.6M	3.2M
Total Stockholder Equity	6.6M	7.0M	9.2M	11.4M	6.1M	6.4M
Property Plant And Equipment Net	16.8K	30.6K	283.4K	172.2K	115.0K	76.8K
Net Debt	(3.7M)	(823.6K)	(7.6M)	(5.9M)	(2.3M)	(2.5M)
Retained Earnings	(100.2M)	(108.3M)	(124.7M)	(134.5M)	(147.0M)	(154.3M)
Accounts Payable	210.3K	434.8K	160.6K	1.0M	206.3K	195.9K
Cash	3.8M	1.2M	7.9M	6.0M	2.5M	4.7M
Non Current Assets Total	5.8M	13.3M	9.1M	11.0M	9.0M	6.1M
Non Currrent Assets Other	114.4K	102.1K	88.0K	82.3K	45.0K	42.8K
Cash And Short Term Investments	3.8M	1.2M	7.9M	6.0M	2.5M	4.7M
Net Receivables	4.9K	91.0K	529.6K	1.4M	2.0M	2.2M
Common Stock Shares Outstanding	79.5K	114.8K	241.1K	732.3K	538.0K	564.9K
Liabilities And Stockholders Equity	10.1M	15.2M	18.1M	18.7M	13.7M	11.7M
Non Current Liabilities Total	2.1M	6.4M	7.2M	4.0M	6.0M	10.2M
Other Current Assets	542.7K	449.6K	1.2M	343.1K	233.4K	416.6K
Other Stockholder Equity	106.7M	116.8M	135.4M	146.0M	153.2M	93.4M
Total Liab	3.5M	8.2M	8.8M	7.3M	7.6M	12.5M
Total Current Assets	4.3M	1.8M	9.0M	7.7M	4.7M	5.6M
Accumulated Other Comprehensive Income	139.5K	(802.0)	(86.4K)	(182.7K)	(182.8K)	(173.7K)
Short Term Debt	83.9K	260.6K	237.7K	211.6K	94.1K	89.4K
Common Stock	40.8K	55.6K	126.6K	18.0K	77.1K	101.9K
Intangible Assets	4.1M	9.7M	8.7M	10.7M	8.8M	7.9M
Other Liab	1.5M	2.1M	6.1M	7.1M	8.2M	8.6M
Net Tangible Assets	7.2M	4.9M	3.3M	9.1M	10.4M	10.9M
Capital Lease Obligations	83.9K	83.9K	209.4K	105.8K	106.9K	96.0K
Net Invested Capital	6.6M	7.3M	9.2M	11.4M	6.1M	7.5M
Non Current Liabilities Other	1.7M	5.3M	6.5M	3.3M	5.1M	3.8M
Net Working Capital	2.9M	37.8K	7.4M	4.4M	3.1M	2.5M
Property Plant Equipment	43.5K	16.8K	30.6K	283.4K	325.9K	342.2K
Capital Stock	40.8K	55.6K	126.6K	18.0K	77.1K	100.8K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Kiora Stock Analysis

When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kiora Begin Period Cash Flow vs Stock Based Compensation Analysis

Begin Period Cash Flow vs Stock Based Compensation

Begin Period Cash Flow vs Stock Based Compensation Correlation Analysis

Correlation Coefficient

Begin Period Cash Flow

Stock Based Compensation

Kiora Pharmaceuticals fundamental ratios Correlations

Kiora Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kiora Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

Additional Tools for Kiora Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 0.98	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Liab	+ 0.97	Non Current Liabilities Total
Other Stockholder Equity	+ 0.95	Total Assets

Total Liab	- 0.99	Total Stockholder Equity
Non Current Liabilities Total	- 0.97	Total Stockholder Equity
Cash And Short Term Investments	- 0.96	Net Debt
Cash	- 0.96	Net Debt
Total Current Assets	- 0.95	Net Debt
Other Liab	- 0.91	Retained Earnings